Pharma Equity Group
0.36 DKK +3.45%HC Andersen Capital receives payment from Pharma Equity Group for a DigitalIR/Corporate Visibility agreement. See disclaimer.
11 investors are following this company
Pharma Equity Group develops new medicines for the local treatment of serious and life-threatening inflammatory diseases for which there is currently no adequate treatment. The company uses repositioning of existing drugs and brings drug candidates to a clinical phase III stage, after which it is handed over to a strategic partner who will complete the development of the products and bring them to market, either independently or in collaboration with the company.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Copenhagen
PEG
Daily low / high price
0.348 / 0.364
DKK
Market cap
368.27M DKK
Turnover
61.61K DKK
Volume
174K
Latest research
Extensive report
Inderes' extensive report is an investor's handbook on customer companies covered by our research.
The latest extensive report was released
Read the reportAnalyst
Claus Thestrup
CEO, Sweden
Financial calendar
General meeting
2024-04-16
Interim report
2024-05-16
Interim report
2024-08-16
Interim report
2024-11-15
ShowingAll content types
Pharma Equity Group A/S (PEG) enters into an agreement with Danske Bank on the exercise of market maker in the PEG share, fund code: DK0061155009
Analyst Group: Equity Research Report on Pharma Equity Group - Clinical Development Progression and Strengthened IP-Portfolio
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools